Compare Amphastar Pharmaceuticals Inc (AMPH) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Financial Select Sector SPDR Fund — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Financial Select Sector SPDR Fund trades at $55.74. The key difference: Financial Select Sector SPDR Fund is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | XLF | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | — |
52-Week High | $30.81 | $56.41 |
52-Week Low | $16.87 | $47.80 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
XLF trades at $55.71, up 0.31% today, with a bullish technical signal from moving averages and strong trend momentum indicated by ADX readings above 55. The ETF is positioned ahead of Q2 bank earnings reports, with news highlighting potential benefits from Federal Reserve rate hikes and recent dividend increases following positive stress test results. Support rests near $55, with resistance at $56.
Outlook is cautiously optimistic as financial sector strength and higher interest rates could drive gains, though overbought RSI levels and geopolitical tensions pose near-term risks. Investor focus remains on earnings performance and macroeconomic policy shifts for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
